Evolv Technologies Holdings, Inc. (EVLV) announced that it has been selected by the American Hospital Association (AHA) as a Preferred Physical Security Provider for hospitals and health systems nationwide. The AHA’s Preferred Provider Program is a rigorous, multi‑step vetting process that evaluates security solutions on performance, reliability, and customer satisfaction. Evolv’s AI‑powered weapons detection systems were the only concealed‑weapon detection provider chosen for the program, underscoring the company’s technological leadership in the healthcare security market.
The partnership expands Evolv’s reach into the healthcare sector, a growing market for advanced security solutions. The company already serves more than 500 hospital buildings and screens millions of individuals each year. By becoming a preferred provider, Evolv gains access to a nationwide network of hospitals that can adopt its Evolv Express® and Evolv eXpedite™ systems, potentially driving recurring revenue from long‑term contracts.
Evolv’s recent financial performance provides context for the partnership’s significance. In Q3 2025, the company reported revenue of $42.85 million, up 57% year‑over‑year, and an earnings per share of –$0.01, a loss that still beat analyst expectations of a –$0.02 loss. The company’s annual recurring revenue (ARR) was $117.2 million, up 25% year‑over‑year, reflecting strong demand for its subscription‑based security platform. The AHA endorsement is therefore a strategic win that could accelerate the company’s recurring revenue trajectory.
Management highlighted the partnership’s importance in a statement. “Healthcare leaders are balancing the critical need for safety with the responsibility to preserve patient access and experience,” said Jason Grellner, VP of Healthcare. “We are honored to be recognized by the AHA and to support hospitals and health systems nationwide as they work to protect the people who depend on them every day.” The quote signals confidence in the company’s ability to meet the stringent security requirements of large health‑system networks.
The partnership comes amid regulatory scrutiny. In November 2024, the Federal Trade Commission imposed a settlement on Evolv for alleged false advertising claims about its AI‑powered screening systems. The settlement restricts the company’s ability to make unsupported claims and offers contract cancellation options to certain school customers. While the AHA endorsement mitigates reputational risk in the healthcare vertical, investors will watch how the company navigates the FTC restrictions and whether it can maintain its growth momentum.
Overall, the AHA selection positions Evolv to deepen its footprint in a high‑growth vertical and to convert its technology into a recurring revenue stream. The partnership signals that the company’s AI‑driven weapons detection platform is meeting the rigorous standards of a major industry association, which could enhance its competitive positioning against rivals such as Metrasens, Rapiscan, and Xtract One Technologies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.